v3.25.2
SEGMENT REPORTING
 3 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 14 – SEGMENT REPORTING

 

The Company manages the business activities on a consolidated basis and operates in one reportable segment. The Company’s reportable segment is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The segment is animal health products. As the Company has one reportable segment, sales and marketing, research and development, including clinical trial expenses and general and administrative expenses are equal to consolidated results. Financial results for the Company’s reportable segment have been prepared using a management approach, which is consistent with the basis and manner in which financial information is evaluated by the Company’s Chief Operating Decision Maker (“CODM”) in allocating resources and in assessing performance. The Company’s CODM is the Chief Financial Officer. The measurement of segment profit or loss that the CODM uses to evaluate the performance of the Company’s segment is net income attributable to animal health. The CODM reviews financial budgets and actual results as assess performance and allocate resources, and makes strategic decisions related to headcount and other expenditures on a consolidated basis. The CODM considers the impact of the significant segment expenses in the table below on operating income (loss) when deciding where and when to make expenditures.

 

   June 30, 2025   June 30, 2024 
   For the Three Months Ended 
   June 30, 2025   June 30, 2024 
NET REVENUE  $297,500   $123,751 
Cost of Sales   110,774    12,994 
Gross Profit   186,726    110,757 
OPERATING EXPENSES          
Sales and marketing   621,712    534,413 
Research and development   1,068,818    1,233,261 
General and administrative   340,513    387,515 
Total operating expenses   2,031,043    2,155,189 
NET OPERATING LOSS  $(1,844,317)  $(2,044,432)